PD-1 Gene Editing


Our promise to you:
Guaranteed product quality, expert customer support.


PD-1 Gene Editing    

PD-1 (programmed cell death protein 1), also named CD279, is an inhibitory receptor expressed by all T cells during activation to control the body's immune response and is one of the most important immunity checkpoints. PD-1 inhibits T cell inflammatory activity and promotes self-tolerance, thereby regulating the immune system's response to human cells. Thus, PD-1 modulates T cell effector functions in a variety of physiological responses, including acute and chronic infections, cancer and autoimmunity, and immune homeostasis (Figure 1).

 Effect of PD-1 on major signaling pathways in T cellsFigure 1: Effect of PD-1 on major signaling pathways in T cells

Studies have shown that PD-1 signaling is one of the main factors in human cancer immune escape. PD-L1 is a PD-1 receptor located on the surface of normal cells and cancer cells. When PD-1 binds to PD-L1, it helps prevent T cells from killing other cells, including cancer cells. Monoclonal antibodies that target PD-1 or PD-L1 block this binding and enhance the immune response of T cells to cancer cells. These drugs show significant efficacy in the treatment of certain cancers, including cutaneous melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. In addition, PD-1 signaling shows great potency in other immune diseases treatment, such as AIDS. But one problem with all these drugs is that they can cause the immune system to attack certain normal organs of the body, which may cause serious side effects in some people. There is still a long way to go for the development and clinical application of anticancer drugs targeting PD-1 signaling.

PD-1 Gene Editing Service

As one of the leading gene editing companies, CRISPR/Cas9 PlatformCB has focused on building efficient systems and procedures to meet the needs and timelines of clients working in the CRISPR/Cas9 gene editing. Our scientists have deep gene editing knowledge and extensive experience in experimental operation and data processing. Based on our platform, CRISPR/Cas9 PlatformCB offers CRISPR/Cas gene editing services and helps you achieve specific gene knockout, knockin, or point mutation in vitro and in vivo within short turnaround time.

  • PD-1 Gene Editing Cell Line Generation

CRISPR/Cas9 PlatformCB has successfully implemented PD-1 CRISPR/Cas9 gene editing both easy-to-transfect cell lines and hard-to-transfect cells. Tell us the cell lines your project needs, we will offer you a one-stop-shop PD-1 gene editing services from strategy design to final cell lines at a reasonable cost and in a shorter time. Our PD-1 gene editing cell line generation services include:

✧ SgRNA design and synthesis
✧ Transfect the cell line you interest
✧ Select the high expression cell and sort monoclonal cell
✧ Validate the knockout/knockin/point mutation of PD-1 by PCR and sequencing
✧ Produce cryogenic preserved vials of stable cells and a final report

Typically, we develop CRISPR-mediated gene editing cell lines, including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.

Host cell line: Ba/F3, CHO, MDA-MB-453, MDA-MB-231NIH3T3, T47D, Neuro2a, MCF7, RKO, K562, RAW264.7, etc.

  • PD-1 Gene Editing Animal Model Generation

CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR-Cas9 technology into animal models, which have been recognized by our clients. We provide you with custom PD-1 CRISPR/Cas gene editing animals and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower cost. Our PD-1 gene editing animal model generation services include:

➢ PD-1 gene conventional knockout animals
➢ PD-1 gene conditional knockout animals
➢ PD-1 point mutation animals
➢ PD-1 knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

Tell us your needs, CRISPR/Cas9 PlatformCB will provide you a professional CRISPR/Cas9 gene editing service. With our national-class labs and gene editing scientists from world-class universities, we guarantee our clients the most reliable and efficient research services to best match your research goals and protect your science investment.

Related Products at CRISPR/Cas9 PlatformCB

CSC-RT2315Human PD1 Knockout Cell Line-JurkatInquiry


  1. Arlene H. Sharpe & Kristen E. Pauken. The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology. 2018. 18: 153–167.
  2. Syn, Nicholas L. et al. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology. 2017. 18 (12): e731–e741.
For research use only. Not intended for any clinical use.


Verification code